Kalliope
Senior Member (Voting Rights)
quotes:
In an article in Brain, researchers from Rutgers University, the National Institutes of Health, Rockefeller University, New York Medical College, the Icahn School of Medicine at Mount Sinai, Stony Brook University, Cold Spring Harbor Laboratory and other institutions contend that studies of infection-associated chronic illnesses suffer recurring problems such as the failure to prove participants have the relevant pathogen.
...
Studies of long COVID, which affects an estimated 9 million Americans, face similar challenges, particularly the tendency to group patients with possible different underlying mechanisms into a single population. Research into myalgic encephalomyelitis/chronic fatigue syndrome is even more difficult because no causative pathogen has been identified.
Yet progress is possible, even without knowledge of the underlying infection. The authors point to multiple sclerosis (MS) as evidence that rigorous study design has yielded helpful FDA-approved treatments.
...
"The framework we advocate is a major step forward since it provides rigorous and well-thought-out guidelines for every aspect of conducting clinical trials in this patient population," said co-author Avindra Nath, physician-scientist and clinical director of the NIH's National Institute of Neurological Disorders and Stroke.
In an article in Brain, researchers from Rutgers University, the National Institutes of Health, Rockefeller University, New York Medical College, the Icahn School of Medicine at Mount Sinai, Stony Brook University, Cold Spring Harbor Laboratory and other institutions contend that studies of infection-associated chronic illnesses suffer recurring problems such as the failure to prove participants have the relevant pathogen.
...
Studies of long COVID, which affects an estimated 9 million Americans, face similar challenges, particularly the tendency to group patients with possible different underlying mechanisms into a single population. Research into myalgic encephalomyelitis/chronic fatigue syndrome is even more difficult because no causative pathogen has been identified.
Yet progress is possible, even without knowledge of the underlying infection. The authors point to multiple sclerosis (MS) as evidence that rigorous study design has yielded helpful FDA-approved treatments.
...
"The framework we advocate is a major step forward since it provides rigorous and well-thought-out guidelines for every aspect of conducting clinical trials in this patient population," said co-author Avindra Nath, physician-scientist and clinical director of the NIH's National Institute of Neurological Disorders and Stroke.
